Guest guest Posted April 9, 2005 Report Share Posted April 9, 2005 Yesterday, April 8, Dr. Zarife Sahenk spoke to a small gathering at Ohio State U about her NT-3 trials; also about the ascorbic acid trial. Slides were shown comparing the nerve ending receptors for severe CMT 1A, healthy subjects, and then with NT-3 and Ascorbic Acid (Vitamin C) Both treatments demonstrated promise in treating the nerve axon. As we all know, future trials are planned - with more participants to see if research still shows such a positive trend. No word was given on " when " the trials will be. However, The U of Rochester has a 5 million $ fundraising project on the table for the Vitamin C/Ascorbic Acid project. Dr. Sahenk will speak more in depth about her discoveries at the Neuropathy Association Conference in Minneapolis next month. For anyone new to who doesn't know what this is about, check back in our archives to October 21, 2003 for the NT-3 news, or go farther back to when the NT-3 trial begain. If you want to know about Ascorbic Acid/Vitamin C, go back in our archives to April 2004 for the research report in Nature, and then read forward for some interesting posts from our membership. We also have a section on Vitamin C in our files now, thanks to Gretchen and , and the entire research report is also there. The focus of this treatment-research is only on CMT 1A, since it is the most common form - I have read 60%, 70% and more recently 75% of CMT is Type 1A. JB Quote Link to comment Share on other sites More sharing options...
Guest guest Posted April 10, 2005 Report Share Posted April 10, 2005 Thanks, JB. It's worth pointing out here though that the vitamin C study was only done on mice. We need those human trials! Fred. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.